Journal of Advance Research in Medical & Health Science (ISSN 2208-2425),
Journal Year:
2023,
Volume and Issue:
9(3), P. 63 - 67
Published: March 10, 2023
Background:
As
a
leading
cause
of
visual
impairment
in
elderly,
age-related
macular
degeneration
has
an
increasing
global
incidence
annually.
It’s
association
towards
cataract
surgery
remains
debate.
Aim:
The
objective
this
study
is
to
summarize
and
evaluate
the
between
degeneration.
Methods:
A
systematic
search
strategy
was
conducted
across
several
electronic
reference
databases
(PubMed,
Cochrane
Library,
ProQuest)
included
articles
published
2018–2023.
Duplicate
publications,
review
articles,
incomplete
were
excluded.
Results:
Databases
searching
identified
total
254
articles.
Of
these,
29
passed
screening
process
resulted
12
for
full-text
assessment.
6
did
not
outcome
interest.
Hence,
we
found
six
appropriate
studies
review.
Conclusion:
results
suggest
that
there
may
be
increased
risk
AMD
progression
development.
This
increase
according
time
follow-up
since
surgery.
To
improve
medical
treatment
patients
with
AMD,
additional
research
essential
understanding
disease
state
its
impact
on
mainly
prospective
multicenter
RCT
studies.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(10), P. 1325 - 1325
Published: Oct. 12, 2024
Eye
disorders
affect
a
substantial
portion
of
the
global
population,
yet
availability
efficacious
ophthalmic
drug
products
remains
limited.
This
can
be
partly
ascribed
to
number
factors:
(1)
inadequate
understanding
physiological
barriers,
treatment
strategies,
and
polymer
properties,
delivery
systems;
(2)
challenges
in
effectively
delivering
drugs
anterior
posterior
segments
eye
due
anatomical
constraints;
(3)
manufacturing
regulatory
hurdles
ocular
product
development.
The
present
review
discusses
innovative
treatments,
encompassing
implants,
liposomes,
nanoparticles,
nanomicelles,
microparticles,
iontophoresis,
situ
gels,
contact
lenses,
microneedles,
hydrogels,
bispecific
antibodies,
gene
strategies.
Furthermore,
this
also
introduces
advanced
technologies
such
as
3D
printing
hot-melt
extrusion
(HME),
aimed
at
improving
bioavailability,
reducing
therapeutic
dosages
side
effects,
facilitating
design
personalized
dosage
forms,
well
enhancing
patient
compliance.
comprehensive
lastly
offers
insights
into
digital
healthcare,
market
trends,
industry
perspectives
pertaining
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(24), P. 13321 - 13321
Published: Dec. 12, 2024
CRISPR–Cas
technology
has
transformed
the
field
of
gene
editing,
opening
new
possibilities
for
treatment
various
genetic
disorders.
Recent
years
have
seen
a
surge
in
clinical
trials
using
CRISPR–Cas-based
therapies.
This
review
examines
current
landscape
implementation
trials,
with
data
from
key
registries,
including
Australian
New
Zealand
Clinical
Trials
Registry,
Chinese
Trial
Register,
and
ClinicalTrials.gov.
Emphasis
is
placed
on
mechanism
action
tested
therapies,
delivery
method,
most
recent
findings
each
trial.
International Ophthalmology Clinics,
Journal Year:
2024,
Volume and Issue:
65(1), P. 47 - 52
Published: Dec. 23, 2024
Age-related
macular
degeneration
(AMD)
is
a
chronic
condition
that
causes
gradual
central
vision
loss,
most
commonly
in
patients
50
years
or
older.
This
disease
classified
as
either
dry
(non-exudative)
wet
(exudative).
Most
with
AMD
have
the
non-exudative
form,
characterized
by
presence
of
drusen
macula.
These
can
be
further
subclassified
based
on
size
into
early,
intermediate,
late
stages.
The
pathogenesis
this
quite
complex
and
has
been
linked
to
genetic
variations,
dysfunction
normal
retinal
homeostasis,
inflammation,
mitochondrial
dysfunction.
Current
treatment
options
for
intermediate
are
limited
lifestyle
modifications
vitamin
supplementation.
Photobiomodulation
therapy
(PBT)
proposed
an
additional
disease.
Early
animal
human
studies
shown
PBT
alter
many
pathways
implicated
including
improving
function,
decreasing
promoting
wound
healing.
Clinical
trials
investigating
use
promising
results.
Many
these
showed
improvement
both
clinical
(visual
acuity
contrast
sensitivity)
well
anatomic
(drusen
volume
area
geographic
atrophy)
variables.
Most,
however,
sample
size,
differences
algorithm,
populations
tested.
Ongoing
aim
expand
work
longer
follow-up,
larger
sizes,
studying
global
population.
Further
needed
determine
ideal
algorithms
patient
may
benefit
from
technology.
Pharmaceuticals,
Journal Year:
2023,
Volume and Issue:
16(4), P. 620 - 620
Published: April 20, 2023
Retinal
degenerative
diseases
such
as
age-related
macular
degeneration
(AMD)
represent
a
leading
cause
of
blindness,
resulting
in
permanent
damage
to
retinal
cells
that
are
essential
for
maintaining
normal
vision.
Around
12%
people
over
the
age
65
have
some
form
disease.
Whilst
antibody-based
drugs
revolutionised
treatment
neovascular
AMD,
they
only
effective
at
an
early
stage
and
cannot
prevent
eventual
progression
or
allow
recovery
previously
lost
Hence,
there
is
clear
unmet
need
find
innovative
strategies
develop
long-term
cure.
The
replacement
damaged
thought
be
best
therapeutic
strategy
patients
with
degeneration.
Advanced
therapy
medicinal
products
(ATMPs)
group
complex
biological
including
cell
products,
gene
tissue
engineered
products.
Development
ATMPs
has
become
fast-growing
field
research
because
it
offers
potential
replace
AMD.
While
shown
encouraging
results,
its
effectiveness
disease
may
hampered
by
body’s
response
problems
associated
inflammation
eye.
In
this
mini-review,
we
focus
on
describing
ATMP
approaches
cell-
gene-based
therapies
AMD
along
their
applications.
We
also
aim
provide
brief
overview
substitutes,
known
scaffolds,
can
used
delivery
target
describe
biomechanical
properties
required
optimal
delivery.
different
fabrication
methods
preparing
cell-scaffolds
explain
how
use
artificial
intelligence
(AI)
aid
process.
predict
combining
AI
3D
bioprinting
cell-scaffold
could
potentially
revolutionise
engineering
open
up
new
opportunities
developing
platforms
deliver
agents
tissues.
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(9), P. 1193 - 1193
Published: Sept. 10, 2024
Natural
products
with
high
antioxidant
activity
are
considered
as
innovative
prevention
strategies
to
effectively
prevent
age-related
macular
degeneration
(AMD)
in
the
early
stage
because
generation
of
reactive
oxygen
species
(ROS)
leading
development
drusen
is
reported
an
important
cause
this
disease.
To
investigate
effects
methanol
extracts
Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 12, 2024
Abstract
Objectives
The
aim
of
the
study
was
to
evaluate
anatomical
and
functional
outcomes
Smaller-Incision
New
Generation
Implantable
Miniature
Telescope
(SING
IMT™)
in
patients
with
bilateral
advanced
age-related
macular
degeneration
(AMD).
Methods
This
non-comparative
retrospective
single-surgeon
interventional
case
series
included
late-stage
AMD
who
underwent
cataract
surgery
SING
IMT™
implantation
at
Sant’Anna
University
Hospital,
Ferrara,
Italy.
main
outcome
measures
corrected
distance
(CDVA)
near
visual
acuity
(CNVA),
endothelial
cell
loss
(ECL),
incidence
complications.
Results
11
eyes
were
included.
mean
follow-up
duration
6.5
±
2.4
months.
After
surgery,
CDVA
significantly
improved
(from
17.00
9.74
26.00
8.53
letters
(P
=
0.008).
Significant
improvement
CNVA
also
observed
12.27
4.36
8
2.61
Jaeger
levels;
P
0.004).
Mean
ECL
4.8
5.5%
3
No
intraoperative
complications
observed,
while
postoperative
iris
incarceration
(9.1%),
pigment
deposition
on
device
transient
corneal
edema
(27.3%).
Nevertheless
10
(90.9%)
began
complain
blurred
or
hazy
vision
within
months
surgery.
ultimately
explanted
(27.3%)
because
this
symptom.
Conclusions
Although
is
associated
promising
objective
results,
unexplained
represent
common
complaints
which
may
lead
patient
dissatisfaction.
Further
studies
including
reported
are
warranted
effect
intervention
patients’
function
quality
life.
